Eli Lilly and partner Boehringer Ingelheim will cut the U.S. list price of the diabetes drug Jardiance and related treatments. The reduction exceeds 40%.
This significant price reduction stands as one of only a handful of cuts planned across the pharmaceutical industry for the upcoming year. The decision is a notable exception to the broader trend of price hikes.
The move places Eli Lilly in a unique position against competitors. For 2026, drugmakers plan to increase prices on at least 350 other branded medications.